Growth Company Investor - Stock market recommendations on AIM and small cap companies

1 June 2016

Latest Share News

A new Angle on cancer diagnostics

Medical device manufacturer Angle (AIM: AGL) has raised a further £10 million through a placing at 64.5p. Angle has an exciting technology which has recently registered its first commercial sales. This extra cash will help to accelerate its marketing efforts and advance the research projects being carried out in major cancer centres.

Motif Bio and the ticking timebomb

The recently published O'Neill report on antimicrobial resistance shows it to be a ticking timebomb. Resistance to antibiotics raises the prospect of 10 million deaths a year by 2050. This is a big opportunity for AIM listed Motif Bio (AIM: MTFB).      

Make mine a double!

Fevertree Drinks (AIM: FEVR) has been one of the most spectacular new issues on AIM in recent years, rising 412 per cent from the float price in late 2014. Today’s trading update served to emphasise why the shares are doing so well and drove them up another 15 per cent.

Fox Marble might be worth the wait 

Fox Marble (AIM: FOX) has raised £2 million through a placing at 10p. The funds will be mainly used to complete its long-delayed marble processing factory in Kosovo. Fox has an exciting story but unfortunately is lagging way behind its original roadmap to profitability.

Business as usual at XL Media 

XL Media (AIM: XLM) has announced the result of its strategic review. I hope no one was holding their breath, because the conclusion is to carry on as usual! The good news is that trading is said to have ‘maintained its excellent start to 2016’.

A Quantum of solace

Quantum Pharma (AIM: QP.) committed the cardinal sin of overpromising and under-delivering during its first year on AIM. New products took longer to come through the regulatory process than expected, which caused downgrades and a share price collapse from a high of 172p last June to the current 58p. However results for the financial year which ended in January suggest the company is getting to grips with the problems in its Niche Pharmaceuticals division.

More News

Popular Topics

Features, research & analysis

Details of NQ minerals IPO revealed 

Advertising feature

Exploration Insights

Ben Jaglom takes a look at the latest action in the mining and oil and gas sector.

Tags: Exploration Insights, Mining, Oil and gas

Fund Manager Focus

David Thorpe takes a look at the strategies of Mark Costar.

Tags: Fund manager focus

More Features

`